Braverman, Nancy E
$1,137,500.00 CAD
≈ 15 Canadians' average pay for a year
- Department
- Canadian Institutes of Health Research
- Program
- Research in Priority Areas
- Recipient country
- Canada
- Fiscal year
- 2024-2025
- Agreement period
- April 1, 2024 – March 31, 2028
- Reference
- cihr-irsc:236-2024-2025-Q1-00982
Published purpose
The specific objectives of this funding opportunity are to: • Increase and advance the development of gene therapies for rare disease clinical trials in Canada; • Generate the evidence required for first-in-human clinical trials, in part by working with Canada’s biomanufacturing capacity (National Research Council of Canada) and health technology regulator (Health Canada); and, • Increase current and future capacity across the Canadian rare disease landscape (i.e., among researchers, knowledge users, patient(s)/caregiver(s)/family) to improve readiness of gene therapies for first-in-human clinical trials.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions